The manager of two cannabis-centric Canadian exchange-traded funds (ETFs) added 18 new cannabis stocks into the two indexes.

On Wednesday (September 26), Horizons ETFs Management completed a quarterly rebalance of the holdings in its two cannabis ETFs— the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) and the Horizons Emerging Marijuana Growers Index ETF (NEO:HMJR).


The Horizons Marijuana Life Sciences Index ETF now holds close to 50 cannabis stocks, while the other index carries 38 stocks.

Cannabis ETFs offer investors a chance to gain a measured exposure into the sector through variety of companies as opposed to picking individual stocks. With the growth of the overall cannabis sector, these offerings have increased as well.

Steve Hawkins, president and CEO of Horizons ETFs, said these rebalances come at a “significant time” for the industry as legalization of recreational cannabis in Canada is scheduled for October 17.

“With recreational sales starting soon, investors will get a better idea of what companies are poised to become leaders in the recreational cannabis space and are able to generate real sales,” Hawkins said in the company’s press release.

The ETF management company has made HMMJ its premier offering while its second cannabis ETF, which launched in February, is solely focussed on smaller market cap North American companies.

“As they grow, these budding marijuana companies have the opportunity to graduate into HMMJ’s index, allowing investors to participate in the full growth cycle of these businesses through our two marijuana based ETFs,” Hawkins explained.

Here’s a list of the stocks HMJR added:

The rise of HMMJ is related to the growth of the holdings it has. The index’s top weighed holdings as of Tuesday (September 25) were: Aurora Cannabis (TSX:ACB), Canopy Growth (NYSE:CGC,TSX:WEED), Aphria (TSX:APH) and GW Pharmaceuticals (NASDAQ:GWPH).

The three Canadian producers have a combined market cap of over C$32 billion, while the pharmaceutical company has raised its profile after obtaining a critical approval in the US for a cannabidiol-based (CBD) medicine.

Here’s all the stocks added to the holdings of HMMJ:

Tilray’s inclusion should add even more value to the index as the Canadian company has enjoyed a substantial rush in the public markets for the past two months.

Investor takeaway

These scheduled quarterly rebalances for the two ETFs offer investors a chance to see which companies have gained the attention from the market and a chance to gain exposure into emerging cannabis industry.

Both HMMJ and HMJR have taken the ups and downs of the cannabis sector volatility but have seen gains so far in 2018. HMMJ raised in value 16.65 percent, over a year-to-date period. As the markets closed on Wednesday’s trading session, HMMJ reached a price of C$24.35.

Since its launch, HMJR has seen an uptick in value thanks to the growth of its holdings. Despite trading on the lesser known Aequitas NEO Exchange, as of 2:30 p.m. EST on Wednesday the holds a price of C$9.27. HMJR has seen a 52-week high price of C$10.48.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Editor’s Note: The headline of this article was changed since it incorrectly stated 17 cannabis stocks were added to the Horizons ETFs.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Ascent Industries, Chemisis International, James E. Wagner Cultivation, Khiron Life Sciences, Maple Leaf Green World, GTEC Holdings, FSD Pharma and INDIVA are clients of the Investing News Network. This article is not paid-for content.

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less